Tolterodine
- Generic Name
- Tolterodine
- Brand Names
- Detrol, Detrusitol
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO
- CAS Number
- 124937-51-5
- Unique Ingredient Identifier
- WHE7A56U7K
- Background
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
- Indication
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
- Associated Conditions
- Urinary Urge Incontinence
- Associated Therapies
- -
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05946902
- Locations
- 🇨🇳
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 805
- Registration Number
- NCT03572231
- Locations
- 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷Site KR410009, Incheon, Korea, Republic of
🇰🇷Site KR410005, Kangam, Korea, Republic of
the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT02599311
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Treatment of Incontinence Without Memory Problems
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 23
- Registration Number
- NCT02436889
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 48
- Registration Number
- NCT02256956
- Locations
- 🇨🇭
Dep. of Anesthesiology, Bern University Hospital, Bern, Switzerland
Genetic Determinants of Amitriptyline Efficiency for Pain Treatment
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 48
- Registration Number
- NCT02256943
- Locations
- 🇨🇭
Dep. of Anesthesiology, Bern University Hospital, Bern, Switzerland
Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
- Conditions
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01964183
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 260
- Registration Number
- NCT01604928
- Locations
- 🇧🇪
Site: 12, Brussels, Belgium
🇧🇪Site: 13, Edegem, Belgium
🇧🇪Site: 11, Gent, Belgium
The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
- Conditions
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- Urmia University of Medical Sciences
- Target Recruit Count
- 104
- Registration Number
- NCT01530243
- Locations
- 🇮🇷
Imam Khomeini Hospital, Urmia, Azerbaijan-gharbi, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.